Peter J. Stogios on Muck Rack

Peter J. Stogios

Toronto
As seen in: Nature, Wiley Online Library, Science Magazine, Cell Chemical Biology, Cell Press, American Society for Microbiology (ASM), The Journal of Biological Chemistry
PhD structural biologist @UofT studying #AMR antimicrobial resistance, #covid19 and protein engineering. #Science is the last best hope of humankind.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Peter J.

Contact Peter J., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Structure-activity Relationship for Diarylpyrazoles as Inhibitors of the Fungal Kinase Yck2

|
By David Shirley, Bonnie Yiu, Peter J. Stogios, Ikeer Mancera-Ortiz
| biorxiv.org
Abstract Candida albicans is a growing global health threat, causing 1.5 million invasive infections and 1 million deaths annually. Yeast casein kinase 2 (Yck2) in C. albicans has emerged as an antifungal target of the kinase inhibitor LY364947 (LY). Herein, we report Yck2 structure-activity relationships for 3,4- and 3,4,5-substituted pyrazole analogs of LY.
Open in Who Shared Issue with article?

Structural and Biochemical Insights into Lignin-Oxidizing Activity of Bacterial Peroxidases against Soluble Substrates and Kraft Lignin

|
By Anna Khusnutdinova, Tatiana Skarina, Peter J. Stogios, Zahra Choolaei
| dx.doi.org
Open in Who Shared Issue with article?

Structure-guided optimization of small molecules targeting Yck2 as a strategy to combat Candida albicans - Nature Communications

|
By Emily Puumala, Peter J. Stogios, Robert Zarnowski, Alexei Savchenko, David Andes, Timothy M. Willson
| Nature Verified
Abstract Candida albicans is the most common cause of life-threatening fungal infection in the developed world but remains a therapeutic challenge. Protein kinases have been rewarding drug targets across diverse indications but remain untapped for antifungal development. Previously, screening kinase inhibitors against C. albicans revealed a 2,3-aryl-pyrazolopyridine, GW461484A (GW), which targets casein kinase 1 (CK1) family member Yck2.
Open in Who Shared Issue with article?
See all 18 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified